cyrilzakka/clinical-trials huggingface dataset:
Augmented Reality in Oral Surgery

A digital workflow was used to assist the oral surgeon in pre-orthodontic exposure of a vestibular impacted canine using Augmented Reality.

Through software for the Object Recognition and Tracking, the researchers expand reality with cone beam computer tomography digital contents to optimize the outcome of surgery. The real-time video frames of the operating field aligned with the three-dimension file of the impacted tooth, were used as a guide to evaluate the surgical access to perform a minimally invasive flap and osteotomy.

This study evaluate an AR-assisted approach for surgical exposure of a maxillary impacted canine. The usual protocol is the following:

* Maxillary arches were scanned, and their occlusal relationship was registered using an optical intraoral scanner.The file was exported in Polygon File Format (PLY)
* Using open-source CAD software, the part of the upper arch was selected from the first premolar to the other first premolars The teeth, the incisal edges and the cusps of the anterior sector were the anatomical markers required to match the patient's mouth and perform the object recognition.To this file that corresponded faithfully to reality we added the digital information required, that is, the position of the impacted crown of the canine
* From the maxillary CBCT, DICOM files were imported in open-source medical software for segmentation and exportation of an STL file of the area of interest
* Two 3D files obtained were imported into a CAD-CAM design software for superimposition. 3D file consisting of the intraoral scan plus the endosseous position of the crown of the impacted canine was exported
* A full HD video camera was positioned in front of the patient's mouth, connected via an HDMI cable to a laptop
* The AR software was then started, and the video camera was associated as an input source The software recognizes edges of files in images transmitted from the camera and overlap the object to the video images.

Eligibility Criteria:
Inclusion Criteria:

* Presence of an impacted tooth in aesthetic area
* Good health according to the System of the American Society of Anesthesiology
* No general medical contraindication for oral surgery
* Good periodontal health

Exclusion Criteria:

* Smoking more than 15 cigarettes a day • Untreated periodontitis
* Pregnancy
* Acute infections
The Lipid Profile of the Skin Surface in Acne

The purpose of this study is to evaluate the differences in the skin lipid profile of patients with and without acne. Secondly, the goal is to learn more about what the effects of retinoinds (topical and systemic) are on the the skin lipid profile. We hypothesize that the skin lipid profile of subjects with acne will be lower in inflammatory lipids in comparison to subjects without acne.

Skin lipid profile will be conducted via sebutapes- adhesive tapes that painlessly absorbs sebum from the face. These tapes will be placed on the face for 1 hour. A photograph of the face will be taken during each study visit. A sebumeter will also be used to measure skin sebum secretion rate.

Eligibility Criteria:
Inclusion Criteria:

* age 12 to 30 years
* have been prescribed tretinoin OR isotretinoin

Exclusion Criteria:

* those who have taken isotretinoin (systemic)
* those who used tretinoin or other topical retinoid within two weeks of starting the study
* those with seborrheic dermatitis, rosacea, or polycystic ovary syndrome
* those who are pregnant, prisoners, or cognitively impaired
* those who do not fit the inclusion criteria
This Study Will Evaluate the Effectiveness of a Simple Intervention Through a Classical Yankauer Oral Suction Tube, in Decreasing the Sedative Medication Doses Needed to Provide Effective Patient Sedation During Bronchoscopy, Along With Its Effect on Both Patient's and Bronchoscopist Satisfaction

The aim of this study is to evaluate the effectiveness of a simple intervention through a classical Yankauer oral suction tube, a device known to have a proven safety profile in multiple healthcare settings, in decreasing the sedative and opioid medication doses needed to provide effective patient sedation during bronchoscopy, along with its effect on both patient's and bronchscopist's satisfaction throughout the procedure.


Eligibility Criteria:
Inclusion Criteria:

* 18 years or above
* inpatients or outpatients
* scheduled to have a flexible bronchoscopy for one of multiple indications based on their physician's assessment, including the presence of a lung mass or collapse, persistent pulmonary infiltrates, pulmonary infection in the setting of immunosuppression, hemoptysis, or other rare causes like chronic cough.
* patients provided a written informed consent.

Exclusion Criteria:

* patients with anatomic oro-pharyngeal abnormalities,
* critically ill patients
* uncooperative patients or inability to provide signed consent by the patient or their legal representative
* coagulopathy or bleeding diathesis
* severe obstructive airway disease
* recent myocardial infarction
* uncontrolled or poorly controlled asthma or chronic obstructive pulmonary disease (COPD)
* pregnancy.
Evaluation of the Safety, Tolerability, and Efficacy of LE051 in Patients With Duchenne Muscular Dystrophy

The purpose of this study is to evaluate the safety, tolerability, and efficacy of LE051 intravenous therapy in DMD patients treated with exon 51 skipping therapy.

This is a single-arm, open-label study to evaluate the safety, tolerability, efficacy, pharmacokinetic, pharmacodynamic, and immune response of LE051 after a single intravenous infusion in DMD patients, as well as the long-term safety and efficacy.

Duchenne muscular dystrophy (DMD) is a progressive neuromuscular disorder arising from mutations in the dystrophin gene, leading to muscle weakness, disability, and premature mortality. LE051, an investigational therapy, incorporates a ADAR recruiting RNA expression cassette targeting human exon 51 and is delivered via adeno-associated virus. By inducing exon 51 skipping, LE051 holds the potential to treat approximately 13% of DMD patients.

Eligibility Criteria:
Key Inclusion Criteria:

* Male，4-8 years old at the beginning of screening (including boundary values;
* DMD subjects with a clinical diagnosis of DMD referred to the Duchenne Clinical Practice Guidelines for Progressive Muscular Dystrophy (2020 edition) and whose genetic test results were confirmed to be applicable to exon skipping at No.51.
* The subjects and/or his guardian voluntary participate in this trial and can comprehend and sign ICF.

Key Exclusion Criteria:

* Clinical signs of heart failure: left ventricular ejection fraction (LVEF) \<40%；
* The average FVC percentage of the predicted value is less than 40%；
* 12 lead ECG QT interval (QTc) \>0.45 seconds.
Use of Hypotension Prediction Index to Reduce Intraoperative Hypotension in Major Thoracic Surgery

Intraoperative hypotension is linked to increased incidence of perioperative adverse events such as myocardial and cerebrovascular infarction and acute kidney injury. Hypotension prediction index (HPI) is a novel machine learning guided algorithm which can predict hypotensive events using high fidelity analysis of pulse-wave contour. Goal of this trial is to determine whether use of HPI can reduce the number and duration of hypotensive events in patients undergoing major thoracic procedures.


Eligibility Criteria:
Inclusion Criteria:

* patients over 18 years of age
* patients scheduled for elective major thoracic procedure (lung resection, pleurectomy or resection of the esophagus)
* planned thoracotomy and intraoperative period of one lung ventilation
* planned postoperative admission to the ICU

Exclusion criteria:

* persistent atrial fibrillation
* structural heart defects (shunting or moderate to severe valvular anomalies)
* preoperative serum hemoglobin levels \< 120 g/L
* severe heart failure classified as New York Heart Association (NYHA) grade IV
Examining the Effect of Virtual Reality on Pain and Anxiety Management During Pelvic Examination

Objective: The study was conducted as a randomized controlled experimental study to examine the effect of the video watched with virtual reality glasses during the pelvic examination on the level of pain and anxiety perceived by women.

Materials-Methods: The sample of the study consisted of 128 women (64 experimental, 64 control group) who applied to the Obstetrics and Gynecology Polyclinics with non-pregnancy complaints between November 2021 and February 2022, volunteered to participate in the study and were approved by the doctor for pelvic examination. Institutional and ethical committee permissions were obtained before starting the study. Descriptive Information Form, State Anxiety Scale, Visual Comparison Scale (GDS), Pelvic Examination Experience Evaluation Questionnaire, and Questionnaire Evaluating Non-Verbal Responses to Emotional Stressful Situations, prepared by the researcher, were used to collect data. In the pre-test to the women in the experimental group of the study: Descriptive Information Form, State Anxiety Scale, Visual Comparison Scale (for anxiety), then Pelvic examination + Virtual reality application (using virtual reality glasses for a minimum of 5 maximum 15 minutes), Emotional Stress to be applied by the researcher The Form Evaluating Non-Verbal Responses to the Creating Situations, and in the post-test: State Anxiety Scale, Visual Comparison Scale (anxiety + pain), Pelvic Examination Experience Evaluation Questionnaire were applied. In the pre-test to the women in the control group of the study: Introductory Information Form, State Anxiety Scale, Visual Comparison Scale (for anxiety), then Pelvic examination (routine service), Form Evaluating Non-Verbal Responses to Emotional Stressing Situations to be administered by the Researcher, In the post-test: State Anxiety Scale, Visual Comparison Scale (anxiety + pain), Pelvic Examination Experience Evaluation Questionnaire were applied. Data were evaluated in computer environment and using SPSS 23.0 statistical package program. A p value of \<.05 for the data was considered statistically significant.


Eligibility Criteria:
Inclusion Criteria:

* Being between the ages of 18-40
* Being able to read and write
* To be competent to express oneself
* Having applied to the outpatient clinic for any gynecological complaint (bleeding, menstrual cycle irregularity, discharge, itching...) or for routine gynecological control.

Exclusion Criteria:

* Having a current pregnancy
* Complaining of acute pelvic pain
* Having any damage or lesion in the perineum that may cause pain during the examination
* Having used a pharmacological agent or method with analgesic or anxiolytic effect 24 hours before the examination
* Having a vaginismus problem
* Having any physical or mental problems that may prevent communication
Role of Angiotensin II in Insulin-induced Microvascular Activity

In this study we hypothesize infusion of Angiotensin II improves the insulin-induced microvascular dilatation and therefore insulin-mediated glucose uptake. Objectives: Does infusion of Angiotensin II increase insulin-mediated glucose uptake via enhanced insulin-mediated microvascular function in healthy subjects?


Eligibility Criteria:
Inclusion Criteria:

1.18-60 years 2.Caucasian 3.Blood pressure \<140/90 mmHg.

Exclusion Criteria:

1. Obesity (BMI\>27kg/m2)
2. Cardiovascular disease (stroke, coronary artery disease, peripheral vascular disease, heart failure)
3. Impaired glucose tolerance or diabetes mellitus according to the criteria of the ADA
4. Smoking
5. Alcohol use \>4U/day
6. Use of medication (antihypertensive drugs, lipid lowering drugs, corticosteroids, NNSAIDs)
7. Pregnancy
8. Wearing contact lenses
Reveal the Patterns of Presentation, Management and Outcome of Patients With SCLC and Stage III NSCLC in Saudi Arabia:

A retrospective, multi-centre, observational study to describe the treatment patterns, the demographic, clinical outcomes, treatment effectiveness, and healthcare resource utilization (HCRU) for patients diagnosed with primary Small Cell Lung Cancer SCLC (Extensive stage \& Limited Stage)and stage III NSCLC in a real-world setting.

A retrospective, multi-centre, observational study to describe the treatment patterns, the demographic, clinical outcomes, treatment effectiveness, and healthcare resource utilization (HCRU) for patients diagnosed with primary Small Cell Lung Cancer SCLC (Extensive stage \& Limited Stage)and stage III NSCLC in a real-world setting

Cohort of patients diagnosed with primary SCLC (limited or extensive stage) or stage III NSCLC, aims to characterize the treatment patterns from the index date (defined as the date of initial diagnosis of locally advanced stage III NSCLC and SCLC) to the end of follow-up (defined as the earliest of death, last available medical record or end of the observation period "defined as the date of data abstraction") including the type of treatment received, duration of each treatment regimen, and reasons for stopping treatment regimen.

The study population will be identified by participating physicians involved in the diagnosis, treatment and management of these patients through the review of established patient medical records. Eligible patients (both alive and deceased) will have their data anonymously abstracted from their medical records into a centrally designed electronic case report form (eCRF).

Eligibility Criteria:
Inclusion Criteria:

* 1. Adult male or female (≥18 years old or according to the age of majority as defined by local regulations).

  2. First-ever diagnosis of lung cancer (absence of previous diagnosis of lung cancer, including SCLC and NSCLC) in the patient's medical records.

  3. Patients either diagnosed with a primary diagnosis of SCLC (extensive or limited) or stage III NSCLC, confirmed by pathology, between 1st of January 2015 and 31st of December 2019.

  4. Medical records available at the participating site reflect at least nine months of follow-up from the index date (unless the patient died within the first nine months of diagnosis)

Exclusion Criteria:

* 1. Patients with concomitant cancer at the time of diagnosis other than SCLC or stage III NSCLC, except for non-metastatic non-melanoma skin cancers, or in situ or benign neoplasms. Cancer will be considered concomitant if it occurs within five years of NSCLC or SCLC diagnosis 2. Patients initially diagnosed with stage I to II NSCLC who have progressed to stage III 3. Current or prior use of "Durvalumab" treatment
Comparison of the Efficacy and Tolerability of Solaraze for 3 Versus 6 Months in Patients With Mild to Moderate Actinic Keratosis Located on the Face and Head

Topical treatment of mild to moderate actinic keratosis located on the face and head with Solaraze® is known to be a safe and efficient treatment option. However, it is unclear if an expansion of the treatment period to 6 months will increase the rate of complete responses.

Therefore the investigators will evaluate the efficacy and safety of the treatment of actinic keratosis with Solaraze® applied twice daily to the face and head over 3 or 6 months of treatment.


Eligibility Criteria:
Inclusion Criteria:

* Visible and histologically proven actinic keratosis
* Prepared and able to give written informed consent
* ≥ 18 -80 years of age
* Prepared and comply with all study requirements, including the following: application of gel on the treatment area twice a day, 5 / 7 clinic visits during the prestudy, treatment, posttreatment, and follow-up period
* Pre- and posttreatment biopsy for histological confirmation (of clearance) of actinic keratosis diagnosis

Exclusion Criteria:

* Data of clinically significant, unstable, cardiovascular or haematologic, hepatic, neurologic, renal, endocrine, collagen-vascular, or gastrointestinal abnormalities or diseases
* Known allergies to any excipient in the study drug
* Any dermatological disease and/or condition in the treatment or surrounding area (3 cm distances from treatment area) that may be exacerbated by treatment with diclofenac or cause difficulty with examination
* Active chemical dependency or alcoholism, as assessed by the investigator
* Currently participating in another clinical study or have completed another clinical study with an investigational drug within the past 30 days
* Received topical treatment at the treatment area with imiquimod or 5-FU within a time period of 1 month
* Invasive tumours within the treatment area, e.g. merkel cell carcinoma, squamous cell carcinoma, basal cell carcinoma, the latter is accepted if completely surgically removed
The Effects of Radium-223 Dichloride Therapy on Radionuclide Bone Scan Lesions.

To describe the changes seen on bone scan and correlate them with changes in relative chemical biomarkers, patient's functional status and level of pain.


Eligibility Criteria:
Inclusion Criteria:

* Prostate cancer patients scheduled for treatment with Radium-223.

Exclusion Criteria:

* Patients not completing their treatment regimen for any reason
Chronic Insertional Achilles Tendonitis Treated With or Without Flexor Hallucis Longus Tendon Transfer

The purpose of this study is to determine whether Achilles tendon debridement and decompression augmented with flexor hallucis longus (FHL) tendon transfer results in improved clinical and functional outcome as measured by ankle plantar flexion strength and American Orthopedic Foot and Ankle Society (AOFAS) score compared to debridement and decompression alone in patients over 50 years of age with chronic insertional Achilles tendinosis.

H0: There will be no difference in ankle plantar flexion strength measured using a handheld dynamometer between patients randomized to achilles tendon decompression and debridement alone (Group 1) and patients randomized to achilles tendon decompression and debridement augmented with FHL transfer (Group 2).

HA: Patients randomized to achilles tendon decompression and debridement alone (Group 1) will have less ankle plantar flexion strength compared to patients randomized to achilles tendon decompression and debridement augmented with FHL transfer (Group 2).


Eligibility Criteria:
Inclusion Criteria:

* Patients 50 years of age or older
* Patients diagnosed with chronic insertional Achilles tendonitis
* Failed greater than 3 months of conservative treatment (activity and shoe modification, heel lifts, non-steroidal anti-inflammatory medications, stretching exercises, and formal physical therapy)

Exclusion Criteria:

* Patients less than 50 years of age upon presentation
* Females of child-bearing potential
* Patients who have a history of ipsilateral Achilles tendon rupture
* History of infection in the same lower extremity
* Patients unable to undergo MRI scan
Safety and Efficacy Study of Cells Sheet-Autologous Chondrocyte Implantation to Treat Articular Cartilage Defects

In this study,the Autologous chondrocyte implantation (ACI)technology and cell sheet technology are used to Cells Sheet-Autologous Chondrocyte Implantation(CS-ACI) for treating Cartilage Defects.The Safety and Efficacy Study of CS-ACI are evaluated.

All procedures are carried out after obtaining informed written consent from patients. Cartilage tissue is acquired from the Non-weight-bearing area of patients. chondrocyte are isolated and grown in culture for 6-8 weeks. After this time interval, the cells are reprocessed and the cell sheet is obtained. Implantation of the chondrocyte sheet into the Cartilage defect of the keen.The patients will be assessed clinically with scoring systems preoperatively as well as 24 months postoperatively to assess relief of symptoms and joint function. Radiological assessment (MRIs)of the affected joints will be performed at the same time points aforementioned to assess integrity of the formed cartilage. Second look arthroscopy and biopsy will also be performed to histologically assess the repair tissue and grade it via arthroscopic grading system according to the International Cartilage Repair Society guidelines.

Eligibility Criteria:
Inclusion Criteria:

* Male or female patients, age: between 18 and 50 years
* Defect: isolated ICRS grade III or IV single defect chondral lesions on Articular Cartilage
* Defect size: 2.5 to \< 5 cm2 after debridement to healthy cartilage up to 6 mm in depth.
* Nearly intact chondral structure surrounding the defect as well as an intact corresponding joint area
* Informed consent signed and dated by patient and Patient understands the strict rehabilitation protocol and follow-up programme and is willing to follow it
* No ligament damage or ligament damage after reconstruction

Exclusion Criteria:

* Patients younger than 18 years and older than 50 years.
* Arthrofibrosis or Ankylosis
* Arthritis
* Obesity
* Infectious diseases
* the other cases of patients which Doctors determine not participate in the trial
Does Application Time Influence the Effect of Massage on Pain and Performance?

Introduction: The massage technique is widely used for post-exercise recovery, however, there is still a gap regarding the ideal dosage in relation to the duration of its application. Objective: To analyze the influence of massage when applied at different times on the dominant (DOM) and non dominant (ÑDOM) quadriceps muscles and clinical variables. Methods: Study carried out with 11 men aged 21.5(2.1) years, in a two-week crossover design. Participants performed a jumping protocol followed by manual massage for 5 (G1) or 10 (G2) minutes. Assessments included strength testing, pain scale (VAS), perception of recovery and vital sign measurements up to one hour post-massage. Analysis onducted in SPSS, ANOVA was performed (with Bonferroni test, when necessary), providing effect sizes (p\<0.05).

The massage technique is widely used for post-exercise recovery, however, there is still a gap regarding the ideal dosage in relation to the duration of its application. The objective was to analyze the influence of massage when applied at different times with the participation of 11 men, in a two-week crossover design. Participants performed a jumping protocol followed by manual massage for 5 (G1) or 10 (G2) minutes. Assessments included strength testing, pain scale (VAS), perception of recovery and vital sign measurements up to one hour post-massage.

Eligibility Criteria:
IInclusion Criteria:

* Students
* Mens
* Aged 18 to 35 years
* Healthy (self-report) regularly enrolled in the Physiotherapy course at the Northern Paraná State University (UENP), from the 1st to the 5th year
* Who have not undergone
* Surgery in the last spine and lower limbs and were instructed not to perform any physical activity in the last 24 hours before the test.

Exclusion Criteria:

* People who are not enrolled in the Physiotherapy course at the State University of Northern Paraná
* Are not in good health
* Have undergone surgery on the lower limbs within a period of 12 months
* Have practiced physical activity in the last 24 hours